Liminatus Pharma, Inc. (LIMN)

NASDAQ: LIMN · Real-Time Price · USD
7.20
+1.98 (37.93%)
At close: Jul 10, 2025, 4:00 PM
7.29
+0.09 (1.25%)
Pre-market: Jul 11, 2025, 8:23 AM EDT
37.93%
Market Cap 187.31M
Revenue (ttm) n/a
Net Income (ttm) -3.55M
Shares Out 26.01M
EPS (ttm) -0.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 826,146
Open 6.01
Previous Close 5.22
Day's Range 5.82 - 7.45
52-Week Range 4.40 - 33.66
Beta 0.57
Analysts n/a
Price Target n/a
Earnings Date n/a

About LIMN

Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPα blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Country United States
Stock Exchange NASDAQ
Ticker Symbol LIMN
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.